Solid Biosciences (SLDB) Stock Price, News & Analysis

Company Overview

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Key Stats

• Today's Range: $6.45 to $6.91
• 50-Day Range: $2.81 to $7.07
• 52-Week Range: $2.41 to $10.37
• Volume: 1.15 million shs
• Average Volume: 1.46 million shs
• Market Capitalization: $529.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.10
• Consensus Rating: Buy

Solid Biosciences Stock Analysis - MarketRank™

Solid Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 466th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Solid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Solid Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Solid Biosciences are expected to grow in the coming year, from ($2.84) to ($2.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Solid Biosciences is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Solid Biosciences is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Solid Biosciences has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.18% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Solid Biosciences has recently increased by 0.89%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solid Biosciences does not currently pay a dividend.

Dividend Growth

Solid Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.18% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Solid Biosciences has recently increased by 0.89%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Solid Biosciences this week, compared to 4 articles on an average week.

Search Interest

48 people have searched for SLDB on MarketBeat in the last 30 days. This is an increase of 153% compared to the previous 30 days.

MarketBeat Follows

34 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 89% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solid Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.90% of the stock of Solid Biosciences is held by insiders.

Percentage Held by Institutions

81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLDB Stock Analysis - Frequently Asked Questions

How have SLDB shares performed this year?

Solid Biosciences' stock was trading at $4.00 at the beginning of 2025. Since then, SLDB shares have increased by 70.8% and is now trading at $6.83.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.06.

When did Solid Biosciences' stock split?

Solid Biosciences shares reverse split on the morning of Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Solid Biosciences IPO?

Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Top institutional investors of Solid Biosciences include Blair William & Co. IL (0.21%), Pallas Capital Advisors LLC (0.01%) and CWM LLC (0.01%). Insiders that own company stock include Perceptive Advisors Llc, Alexander Cumbo, Kevin Tan, Carl Ashley Morris, David T Howton, Jessie Hanrahan, Ilan Ganot, Gabriel Brooks, Paul Herzich and Clare Kahn.
View institutional ownership trends.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLDB
• CIK: 1707502
• Web: www.solidbio.com
• Phone: (617) 337-4680
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Solid Biosciences: $15.10
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +121.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$124.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -68.15%
• Return on Assets: -55.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.89
• Quick Ratio: 10.89

Sales & Book Value

• Annual Sales: $8.09 million
• Price / Sales: 65.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.43 per share
• Price / Book: 1.99

Miscellaneous

• Outstanding Shares: 77,510,000
• Free Float: 76,042,000
• Market Cap: $529.39 million
• Optionable: Optionable
• Beta: 2.43